Link: https://links.sgx.com/1.0.0/corporate-announcements/N7G9WC70EBF2806Y/baf3a836435025d60a989de555fe675be049fd2e2c43cd02199be7aaf7f51f0b

Summary:

• Vicplas International expects to report a consolidated net loss for the financial year ended 31 July 2025.

• Loss is mainly due to:

  • Lower positive results from the pipes and pipe fittings segment.

  • Continued negative results from the medical devices segment, including start-up and ramp-up costs at the Mexico plant and ongoing costs at the Changzhou plant extension.

  • Higher finance costs.

• Medical devices revenue grew, but profit constrained by new plant costs as Mexico and China facilities ramp up utilization.

• Pipes and fittings segment benefited from strong construction activity in Singapore but faced increased competition and credit risk.

• Group’s adjusted EBITDA for FY2025 is expected to remain positive and exceed S$4.4 million reported for 1H FY2025.

• The medical devices segment continues to invest in scaling up global operations.

• Final FY2025 results are expected on or before 29 September 2025; shareholders advised to exercise caution.